Ovid Therapeutics Inc.
Ovid Therapeutics Inc. (OVID): 4 pipeline candidates · ~34 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
33.5 months
D/E 0.14 · 0% dilution
Lead: Phase 2
4 candidates
N/A
0 buys · 2 sells (180d)
A transparent, data-derived signal for Ovid Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$439.5M
Cash
$96.0M
Quarterly Burn
$13.9M
Runway
33.5 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
102
Total value held
$260.7M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 21,428,000 | $47.5M |
| ra capital management, l.p. | 10,714,000 | $23.8M |
| affinity asset advisors, llc | 10,636,318 | $23.6M |
| vanguard capital management llc | 10,516,492 | $23.3M |
| eventide asset management, llc | 9,916,911 | $22.0M |
| adage capital partners gp, l.l.c. | 6,163,781 | $13.7M |
| balyasny asset management l.p. | 5,533,073 | $12.3M |
| adar1 capital management, llc | 4,544,113 | $10.1M |
| federated hermes, inc. | 3,571,000 | $7.9M |
| ikarian capital, llc | 2,894,704 | $6.4M |
Showing top 10 of 102 institutional holders of Ovid Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Ovid Therapeutics Inc.'s pipeline?
Ovid Therapeutics Inc. (OVID) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ovid Therapeutics Inc.'s lead drug candidate?
Ovid Therapeutics Inc.'s most advanced tracked candidate is ov329 (Phase 1) for drug-resistant epilepsies.
What is Ovid Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ovid Therapeutics Inc. has approximately 33.5 months of cash runway.
What is Ovid Therapeutics Inc.'s market capitalization?
Ovid Therapeutics Inc.'s market capitalization is approximately $439.5M.
Who is the CEO of Ovid Therapeutics Inc.?
Ms. Margaret Alexander is the chief executive officer of Ovid Therapeutics Inc. (OVID).
Get the full picture on Ovid Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.